SCHEMBL273404

SCHEMBL273404

COc1ccc(F)cc1C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.56
ALDH1A1 P00352 5/20 0.55
TSHR P16473 2/20 0.55
KDM4E B2RXH2 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPT P10636 1/20 0.50
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 1/20 0.48
NFE2L2 Q16236 2/20 0.47
TLR2 O60603 1/20 0.47
TLR1 Q15399 1/20 0.47
TLR6 Q9Y2C9 1/20 0.47
AR P10275 1/20 0.47
TUBB1 Q9H4B7 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29432755 1.00 ERN1 (0.56) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL6098384 0.85 ALDH1A1 (0.63) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL365682 0.84 ALDH1A1 (0.63) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL25688773 0.84 CYP1A2 (0.53) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL275895 0.83 ALDH1A1 (0.66) ERN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL9049946 0.83 NFE2L2 (0.55) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL18177606 0.82 ERN1 (0.62) ERN1ALDH1A1TSHRKDM4ETDP1
SCHEMBL8686048 0.80 ALDH1A1 (0.55) ERN1ALDH1A1KDM4EMAPTMEN1
SCHEMBL29750759 0.80 ALDH1A1 (0.55) ERN1ALDH1A1KDM4EMAPTMEN1
SCHEMBL21816457 0.80 ALDH1A1 (0.55) ERN1ALDH1A1KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111592535-B Preparation method of EGFR mutation resistant inhibitor EAI045 通化师范学院 2021-07-20 CN claimed
CN-111592535-A Preparation method of EGFR mutation resistant inhibitor EAI045 通化师范学院 2020-08-28 CN claimed
US-12630511-B2 Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-05-19 US disclosed
EP-4707264-A2 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS Verbio SE (DE) 2026-03-11 EP disclosed
EP-4122924-B1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2025-11-19 EP disclosed
US-12454532-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) FORMA THERAPEUTICS, INC. (US) 2025-10-28 US disclosed
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2025-10-23 US disclosed
US-20250304583-A1 INHIBITING G CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) FORMA THERAPEUTICS, INC. 2025-10-02 US disclosed
US-12378242-B2 Inhibiting CREB binding protein (CBP) FORMA THERAPEUTICS, INC. (US) 2025-08-05 US disclosed
WO-2025124496-A1 COMPOUND CONTAINING PYRAZOLE RING AND BICYCLIC HETEROARYL GROUP, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 正大天晴药业集团股份有限公司 2025-06-19 WO disclosed
CN-119816484-A Novel piperazine derivative or salt thereof and pharmaceutical composition 富士胶片株式会社 2025-04-11 CN disclosed
US-4772625-A 1,3-dioxan-5-yl-hexenoic acids IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-09-20 US disclosed
EP-0266980-A2 Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-05-11 EP disclosed
EP-0225175-A2 Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof FISONS plc (GB) 1987-06-10 EP disclosed
EP-0202086-A2 Hexenoic acids IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-20 EP disclosed
EP-0201354-A2 2,4-Diphenyl-1,3-Dioxanes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-12 EP disclosed
US-4448971-A Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1984-05-15 US disclosed
US-4407811-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1983-10-04 US disclosed
US-4399296-A TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES PFIZER INC. (US) 1983-08-16 US disclosed
US-4367234-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1983-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304583-A1 INHIBITING G CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) CREBBP, CREB1, EP300 ERN1 650/4885ALDH1A1 3783/4885TSHR 2531/4885
US-12378242-B2 Inhibiting CREB binding protein (CBP) CREBBP, EP300, CREB1 ERN1 637/4885ALDH1A1 3592/4885TSHR 2892/4885
US-12630511-B2 Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer EGFR, ERBB2, KRAS ERN1 4044/4885ALDH1A1 1072/4885TSHR 1637/4885
US-12454532-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) CREBBP, CREB1, EP300 ERN1 593/4885ALDH1A1 3548/4885TSHR 2457/4885
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION ABCB11, ABCC1, SLC11A2 ERN1 3094/4885ALDH1A1 774/4885TSHR 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.